RNA疫苗-话题@MedSci

#RNA疫苗#

127篇内容 | 1298人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2177169, encodeId=512d21e716998, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=ae97180090b' target=_blank style='color:#2F92EE;'>#T细胞#</a> <a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=读书报告 | 个体化新抗原RNA疫苗活化胰腺癌T细胞, objectType=article, longId=806866, objectId=62ef806866b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301012/1697148713785_4754896.jpeg, objectUrl=/article/show_article.do?id=62ef806866b9, replyNumber=0, likeNumber=28, createdTime=2023-12-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=62ef806866b9, moduleTitle=读书报告 | 个体化新抗原RNA疫苗活化胰腺癌T细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62ef806866b9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1947479, encodeId=994e194e479cb, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请, objectType=article, longId=736670, objectId=313be36670fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313be36670fc, replyNumber=0, likeNumber=62, createdTime=2022-09-02, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313be36670fc, moduleTitle=辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313be36670fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947483, encodeId=ce04194e483b7, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, objectType=article, longId=739304, objectId=992ee39304e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=992ee39304e3, replyNumber=0, likeNumber=48, createdTime=2023-03-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=992ee39304e3, moduleTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=992ee39304e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947481, encodeId=5734194e48186, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=NEJM：mRNA疫苗加强针的保护作用持久性研究, objectType=article, longId=738574, objectId=b412e3857484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b412e3857484, replyNumber=0, likeNumber=50, createdTime=2022-09-13, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b412e3857484, moduleTitle=NEJM：mRNA疫苗加强针的保护作用持久性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b412e3857484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947480, encodeId=3b64194e4803f, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Moderna递交Omicron特异性mRNA疫苗mRNA-1273.222紧急使用授权申请, objectType=article, longId=736906, objectId=625fe3690684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625fe3690684, replyNumber=0, likeNumber=61, createdTime=2022-11-30, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625fe3690684, moduleTitle=Moderna递交Omicron特异性mRNA疫苗mRNA-1273.222紧急使用授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=625fe3690684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947482, encodeId=8b02194e48207, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Cell Rep Med：异源接种新冠灭活疫苗+mRNA疫苗加强针，效果良好, objectType=article, longId=739346, objectId=0e1de39346db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1de39346db, replyNumber=0, likeNumber=61, createdTime=2023-06-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1de39346db, moduleTitle=Cell Rep Med：异源接种新冠灭活疫苗+mRNA疫苗加强针，效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1de39346db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947470, encodeId=2f21194e47011, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JAMA Cardiology：mRNA疫苗后遗症（心肌炎）偏爱16-24岁年轻男性, objectType=article, longId=725532, objectId=b0d0e2553280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0d0e2553280, replyNumber=0, likeNumber=51, createdTime=2023-01-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0d0e2553280, moduleTitle=JAMA Cardiology：mRNA疫苗后遗症（心肌炎）偏爱16-24岁年轻男性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0d0e2553280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947458, encodeId=3fa8194e45858, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=美国FDA或将在本周批准为50岁以上人群接种第四剂mRNA疫苗, objectType=article, longId=301842, objectId=36a03018424a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36a03018424a, replyNumber=0, likeNumber=42, createdTime=2022-05-14, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36a03018424a, moduleTitle=美国FDA或将在本周批准为50岁以上人群接种第四剂mRNA疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36a03018424a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947473, encodeId=a224194e473f4, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=尴尬的中国mRNA疫苗，还有好日子吗？, objectType=article, longId=726374, objectId=b767e263740f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b767e263740f, replyNumber=0, likeNumber=46, createdTime=2023-01-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b767e263740f, moduleTitle=尴尬的中国mRNA疫苗，还有好日子吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b767e263740f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947474, encodeId=6417194e47441, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=物传人的概率为空气传播的千分之一，我国自主研发的mRNA疫苗获批临床试验丨新冠研究一周进展, objectType=article, longId=726406, objectId=7befe264069b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7befe264069b, replyNumber=0, likeNumber=64, createdTime=2022-05-28, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7befe264069b, moduleTitle=物传人的概率为空气传播的千分之一，我国自主研发的mRNA疫苗获批临床试验丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7befe264069b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947478, encodeId=d333194e478a4, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕, objectType=article, longId=735859, objectId=3eebe358592e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eebe358592e, replyNumber=0, likeNumber=54, createdTime=2023-04-17, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eebe358592e, moduleTitle=上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eebe358592e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947453, encodeId=0b77194e4538f, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Cell Research：秦成峰团队发布Omicron特异性mRNA疫苗动物实验数据, objectType=article, longId=299275, objectId=50442992e540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50442992e540, replyNumber=0, likeNumber=53, createdTime=2022-06-17, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50442992e540, moduleTitle=Cell Research：秦成峰团队发布Omicron特异性mRNA疫苗动物实验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50442992e540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947450, encodeId=6396194e450f5, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Moderna旗下的HIV mRNA疫苗试验顺利进行, objectType=article, longId=295022, objectId=eb6e2950223d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb6e2950223d, replyNumber=0, likeNumber=50, createdTime=2022-05-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb6e2950223d, moduleTitle=Moderna旗下的HIV mRNA疫苗试验顺利进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb6e2950223d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947477, encodeId=3bcc194e47768, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JNNP:在接受芬戈莫德治疗的多发性硬化症患者中，SARS-CoV-2 mRNA疫苗接种未能引发体液和细胞免疫反应, objectType=article, longId=734385, objectId=84d8e34385a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d8e34385a7, replyNumber=0, likeNumber=64, createdTime=2023-04-06, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d8e34385a7, moduleTitle=JNNP:在接受芬戈莫德治疗的多发性硬化症患者中，SARS-CoV-2 mRNA疫苗接种未能引发体液和细胞免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84d8e34385a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947461, encodeId=1b1c194e46103, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？, objectType=article, longId=723495, objectId=6007e23495f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6007e23495f7, replyNumber=0, likeNumber=36, createdTime=2023-03-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6007e23495f7, moduleTitle=上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6007e23495f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947476, encodeId=3d1b194e47629, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=NEJM：辉瑞mRNA疫苗对儿童预防奥密克戎感染和症状的真实世界效果, objectType=article, longId=730993, objectId=2fb2e30993af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fb2e30993af, replyNumber=0, likeNumber=52, createdTime=2023-03-14, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fb2e30993af, moduleTitle=NEJM：辉瑞mRNA疫苗对儿童预防奥密克戎感染和症状的真实世界效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fb2e30993af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947445, encodeId=61fa194e44526, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=NEJM：BNT162b2 mRNA疫苗接种后心肌炎风险为每100000人2.13例, objectType=article, longId=221512, objectId=3110221512b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3110221512b0, replyNumber=0, likeNumber=64, createdTime=2022-08-20, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3110221512b0, moduleTitle=NEJM：BNT162b2 mRNA疫苗接种后心肌炎风险为每100000人2.13例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3110221512b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947456, encodeId=a6de194e4565e, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JAMA：孕妇接种mRNA疫苗，抗体会传给孩子并保持至少6个月, objectType=article, longId=299657, objectId=e03e29965e35, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e03e29965e35, replyNumber=0, likeNumber=46, createdTime=2023-02-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e03e29965e35, moduleTitle=JAMA：孕妇接种mRNA疫苗，抗体会传给孩子并保持至少6个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e03e29965e35)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947469, encodeId=64bd194e469da, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Thyroid：甲状腺功能减退患者中接种COVID-19灭活和mRNA疫苗的安全性分析, objectType=article, longId=724846, objectId=f8cfe2484625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8cfe2484625, replyNumber=0, likeNumber=71, createdTime=2022-12-22, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8cfe2484625, moduleTitle=Thyroid：甲状腺功能减退患者中接种COVID-19灭活和mRNA疫苗的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8cfe2484625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947433, encodeId=8655194e433ec, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JNNP：多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫, objectType=article, longId=219212, objectId=25c4219212b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25c4219212b0, replyNumber=0, likeNumber=51, createdTime=2022-01-08, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25c4219212b0, moduleTitle=JNNP：多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25c4219212b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RNA疫苗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #T细胞# #RNA疫苗#

读书报告 | 个体化新抗原RNA疫苗活化胰腺癌T细胞

2023-12-25发表于上海

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请

2022-09-02

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼

2023-03-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

NEJM：mRNA疫苗加强针的保护作用持久性研究

2022-09-13

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Moderna递交Omicron特异性mRNA疫苗mRNA-1273.222紧急使用授权申请

2022-11-30

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Cell Rep Med：异源接种新冠灭活疫苗+mRNA疫苗加强针，效果良好

2023-06-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JAMA Cardiology：mRNA疫苗后遗症（心肌炎）偏爱16-24岁年轻男性

2023-01-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

美国FDA或将在本周批准为50岁以上人群接种第四剂mRNA疫苗

2022-05-14

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

尴尬的中国mRNA疫苗，还有好日子吗？

2023-01-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

物传人的概率为空气传播的千分之一，我国自主研发的mRNA疫苗获批临床试验丨新冠研究一周进展

2022-05-28

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕

2023-04-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Cell Research：秦成峰团队发布Omicron特异性mRNA疫苗动物实验数据

2022-06-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Moderna旗下的HIV mRNA疫苗试验顺利进行

2022-05-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JNNP:在接受芬戈莫德治疗的多发性硬化症患者中，SARS-CoV-2 mRNA疫苗接种未能引发体液和细胞免疫反应

2023-04-06

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？

2023-03-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

NEJM：辉瑞mRNA疫苗对儿童预防奥密克戎感染和症状的真实世界效果

2023-03-14

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

NEJM：BNT162b2 mRNA疫苗接种后心肌炎风险为每100000人2.13例

2022-08-20

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JAMA：孕妇接种mRNA疫苗，抗体会传给孩子并保持至少6个月

2023-02-03

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Thyroid：甲状腺功能减退患者中接种COVID-19灭活和mRNA疫苗的安全性分析

2022-12-22

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JNNP：多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫

2022-01-08

科室
- - 订阅+
  - 更多科室
工具
服务